Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX-6 plus cetuximab versus induction mFOLFOX-6 plus cetuximab followed by cetuximab maintenance in first-line KRAS wild-type metastatic colorectal cancer
2009-017194-38Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Mar 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, oxaliplatin, folinic acid and fluorouracil in colorectal cancer (CRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-free at 9 months. Started Mar 2010; status: completed.
02
Drugs
cetuximaboxaliplatinfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-017194-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017194-38.